CN 40-2023 - Amendments to Chapters 7 and 9 v1.pdf (380KB)
Click on the image below to hear the audio version of receiving a Blood Transfusion. The different sections of this recording appear at the following times (mins/secs):
JPAC - About Us (Dec 2023).pptx (4MB)
JPAC Position Statement on HHV-8 - October 2023.pdf (134KB)
9.7: Recommended standards for environmental monitoring (EM) of processing facilities EM programmes must be in place for both uncontrolled and controlled (GMP graded areas) processi…
9.4: Reinstatement of blood donors Where a blood donation sample is found to be repeatedly reactive on screening (except for anti-HCMV), the donation and any components must not be relea…
9.2: Microbiology screening Note: The meanings of certain terms used in this section are defined in section 9.2.6. 9.2.1: Screening of donations/donors Donation/donor…
Minutes of the JPAC meeting 22-06-2023.pdf (174KB)
Click on the text below to download a translated copy of the patient information leaflet:
Receiving a blood transfusion_Ukrainian.pdf (602KB)
dsg_wb_203_002_69_41_ol_01.zip (6MB)
2.7: Reporting of incidents to external bodies 2.7.1: Serious Hazards of Transfusion (www.shotuk.org) For blood components, serious advers…
2.6: Quality management system Note that where key advice is given elsewhere in the guidelines, the relevant sections have been cross-referenced. Where there is not a direct cross-refere…
CN 39-2023 - Amendments to Red Book Annexe 7 v1.pdf (241KB)
22.11: Record Maintenance All patient records and results should be maintained to comply the requirements of the GDPR.
22.10: Disposal of haemopoietic progenitor cells Disposal of cellular therapy products shall include the following requirements shall meet the EBMT guideline requiments (Chapter D12: Dis…
22.5: Donor selection, consent and testing Establishments must have detailed policies and procedures for the testing and assessment of donors of stem cells. These must be in accordance w…
22.4: Adverse events and reactions 22.4.1: HTA Guide for the management of serious adverse events (SAEs) and reactions (SARs) All licensed establishments must have a system in…
22.3: Policy and procedure requirements and Safety 22.3.1: HTA licensing and requirements The procurement and testing of human tissues or cells in UK should only be carried ou…
22.2: Terminology This chapter aligns with the terminology described at FACT-JACIE International Standards for Haemopoietic Cellular Therapy, Product Collection, Processing,…
22.6: Collection, processing and storage Stem Cells and Therapeutic Cells should only be collected in a hospital facility or Blood Service apheresis unit with appropriate experience (see…
JPAC Position Statement on Zika - September 2023.pdf (118KB)
CN 34-2023 - France, Italy and Spain (WNV & Dengue) v1.pdf (2MB)